SCHEMBL2933192

SCHEMBL2933192

CCOC(=O)c1ccn(Cc2ccc(C(=N)NO)c(Cl)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
HDAC1 Q13547 4/20 0.39
HPGD P15428 2/20 0.39
HDAC7 Q8WUI4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
CACNA1G O43497 1/20 0.37
CACNA1H O95180 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2935358 0.89 HPGD (0.40) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL2935227 0.85 ALDH1A1 (0.44) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL13178015 0.82 KMT2A (0.41) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL2936546 0.80 KMT2A (0.51) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL2936285 0.78 KMT2A (0.44) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL2936428 0.78 AR (0.45) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL16578878 0.78 ALDH1A1 (0.49) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL28698821 0.76 ALDH1A1 (0.50) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL30317956 0.75 NPC1 (0.49) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL18338361 0.75 LMNA (0.65) KMT2AMEN1NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091950-B1 OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS GLAXO GROUP LTD (GB) 2010-09-22 EP disclosed
US-20100048639-A1 OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2010-02-25 US disclosed
EP-2091950-A1 OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS Glaxo Group Limited (GB) 2009-08-26 EP disclosed
WO-2008074820-A1 OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048639-A1 OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS S1PR1, S1PR3, S1PR2 KMT2A 4133/4885MEN1 1833/4885NPC1 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.